Innovative
Solutions

That Provide
Better Outcomes

Long-term

Fiscally Sustainable Solutions

Industry-leading
Methods

To Protect Employees
And Your Bottom Line

Latest News

    • 12 JUL 17
    • 0
    WILL THE NEW FDA COMMISSIONER HELP PHARMACY BENEFIT MANAGERS?

    WILL THE NEW FDA COMMISSIONER HELP PHARMACY BENEFIT MANAGERS?

    Several changes within the federal government have been taking place this year and perhaps none are of more interest to Pharmacy Benefit Managers (PBMs) than the recent change to the Food and Drug Administration (FDA) Commissioner role. Scott Gottlieb, M.D., has been named the new FDA commissioner and has the opportunity to impact both PBMs and

    • 07 JUL 17
    • 0
    MICHIGAN AUTO INSURANCE PREMIUMS IN THE TOP 3 OF THE NATION

    MICHIGAN AUTO INSURANCE PREMIUMS IN THE TOP 3 OF THE NATION

    Residents in the state of Michigan are no strangers to the fact that the cost of their auto insurance premiums has been on the rise. In fact, The Detroit Free Press reported that auto insurance premiums in Michigan have been increasing since the year 2009. Insure.com provided information showing that Michigan’s auto insurance rates were

    • 06 JUL 17
    • 0
    C-THRU Act Would Increase Federal Spending by $20 Billion

    C-THRU Act Would Increase Federal Spending by $20 Billion

    Senate Finance Committee Ranking Member Ron Wyden (D- Ore.) introduced the C-Thru Act which would require a greater transparency between entities such as pharmacy benefit managers (PBMs) and pharmaceutical companies regarding rebates they receive on behalf of their health plan clients. While it is considered common knowledge that PBMs negotiate rebates, it is unclear how they

    • 29 JUN 17
    • 0
    PHARMACY BENEFIT MANAGERS’ ROLE WITH DISPENSE AS WRITTEN DRUGS

    PHARMACY BENEFIT MANAGERS’ ROLE WITH DISPENSE AS WRITTEN DRUGS

    Prescription medicines are costly and a significant source of concern for insurance companies administering workers’ compensation and automobile no-fault claims. Within the healthcare and insurance industries there exists some debate concerning the substitution of generic for dispense as written drugs (DAW) orders for specific brand name drugs. According to The Washington Post, non-generic prescription drugs cost nearly eight billion dollars per year